ASCO Solid Tumors 2022 – Kohei Shitara

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Kohei Shitara talks about new promising agents in the treatment of advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma and how existing drugs can blend into these new regimens. He overviews the current state of prognostic and predictive biomarker in gastric cancer and gives an outlook on new biomarkers that are on the rise to guide therapy while finally summarizing his personal medical and scientific highlights at this year’s ASCO meeting.

Here is the full ASCO 2022 Solid Tumors report.